Human Anti-Lipopolysaccharide IgA

Your gut holds trillions of bacteria that are supposed to stay behind the intestinal wall. When that wall weakens, fragments of those bacteria leak into your bloodstream, and your immune system answers by making antibodies against them. This test measures one of those antibodies, giving you a window into whether that leakage is happening.

The same antibody is also one of the sharpest blood signals for active typhoid fever in parts of the world where that infection is common. Depending on your situation, one number can point to a recent gut infection, a chronically leaky gut, or long-running low-grade immune activation.

What This Antibody Actually Measures

This test measures anti-LPS IgA (anti-lipopolysaccharide immunoglobulin A). Lipopolysaccharide, often called endotoxin, is the molecule that coats the outer surface of many gut bacteria. IgA is the class of antibody your body concentrates at moist surfaces like the lining of your gut, where it acts as a first line of defense.

Most of this antibody is made by immune cells in the tissue around your intestines, then some of it makes its way into the blood. Because of that origin, a blood level of anti-LPS IgA is generally read as a marker of how much bacterial endotoxin your gut lining has been meeting, rather than a direct measure of any single disease.

This is a research and specialty marker rather than a routine panel test. There are no universally agreed cutoffs for general health, and a single reading should not drive decisions on its own. That is exactly why a baseline value and a trend over time are more useful than one snapshot.

A Strong Signal for Typhoid Fever

The clearest evidence for this antibody is diagnostic. In people with typhoid fever, blood anti-LPS IgA rises sharply. In studies comparing confirmed typhoid cases against healthy people, it flagged roughly 96 out of 100 cases and cleared a similar share of healthy people, using bacterial blood culture as the reference. That is a best-case figure drawn from comparisons against healthy volunteers, and some of it comes from tests that combine this antibody with other typhoid markers. In typhoid-endemic settings, the antibody used on its own has performed less well, with some studies catching only about half of cases at a comparable specificity.

The headline number also narrows in real clinical life. When the comparison group was people with other fevers rather than healthy volunteers, accuracy dropped to roughly 87 out of 100 cases caught and 84 out of 100 non-cases cleared. Separating typhoid from dengue or malaria is the harder and more useful problem, and the antibody is good but not definitive there.

Gut Barrier Breakdown and Stalled Growth

In settings where the gut lining is chronically inflamed, higher anti-LPS IgA tracks with worse outcomes rather than with diagnosis. In a study of infants in rural Pakistan, those with higher levels early in life showed significantly greater declines in linear growth over the following months than infants with the lowest levels, even after accounting for other factors. In a separate study of young Tanzanian children, those with the highest early levels were about 1.8 times more likely to become underweight.

Anti-LPS IgA in those infants also moved in step with general inflammation markers in the blood and gut. The pattern fits a picture where a persistently leaky, inflamed gut keeps exposing the immune system to endotoxin, and that steady exposure carries a cost for growth and development.

The Liver Cancer Puzzle

Here is a finding that seems to cut against the grain. A large pooled analysis of 12 groups found that this specific antibody, anti-LPS IgA, was not associated with future liver cancer risk, even though a related antibody, anti-LPS IgG, was. Other cohorts have not agreed: an earlier study in Finnish male smokers found anti-LPS IgA was linked to higher liver cancer risk, so the evidence here is genuinely mixed rather than settled. Still, the split between the two antibody types helps reveal what each one means.

IgA is the immune system's local, mucosal responder, concentrated at surfaces like the gut. IgG is the systemic responder that dominates once bacteria have truly breached the barrier and spread through the body. So anti-LPS IgA reflects gut-level immune activity, while IgG better captures sustained whole-body bacterial spillover. Neither is a simple good or bad number; each reports on a different stage of the same process, which is why they can behave differently for different diseases.

Chronic Inflammatory Conditions

Beyond the gut, this antibody shows up as a marker of chronic bacterial exposure. In people with gum disease, blood IgA against the endotoxin of a key oral bacterium was significantly higher than in people with healthy gums, consistent with ongoing immune exposure from the mouth.

In rheumatoid arthritis, anti-LPS IgA levels shifted alongside other markers of oral and gut bacterial activity, supporting the idea that microbial exposure feeds into the disease's biology. And in sera positive for certain inflammatory bowel disease antibodies, IgA against endotoxin was elevated in about 30 to 33 out of 100 samples, compared with roughly 9 to 12 out of 100 in controls.

What this means for you: the same antibody carries different meaning depending on your context. In an acute febrile illness it points toward infection; in a chronic setting it more often signals ongoing gut or oral bacterial exposure. Interpretation depends on why you are testing, not on a single universal threshold.

Why One Reading Rarely Tells the Whole Story

This marker moves with your immune state, so a single value is a snapshot of a moving target. After an infection, blood anti-LPS IgA can stay elevated for months before declining, which means one high reading cannot tell you whether you are in the middle of something acute or trailing off from a past exposure. The exact timing is not precisely mapped for serum anti-LPS IgA, but typhoid antibody studies suggest a window on the order of a few months.

Tracking the trend is where the value lies. A practical approach is to establish a baseline, retest in 3 to 6 months if you are actively addressing gut health or recovering from an infection, and then at least once a year. Because this is a newer measurement without settled cutoffs, your own trajectory becomes your reference point, and that head start compounds as the science matures.

When a Single Result Can Mislead You

• Low total IgA: roughly 1 in 500 people make very little IgA of any kind. If your overall IgA is low, your anti-LPS IgA will read low regardless of gut exposure, so a total IgA level is worth checking alongside it.
• Recent infection: any recent gut or gram-negative infection can push levels up, and they can stay elevated for months, so a high value may reflect a past event rather than a current one.
• Cross-reactivity: this antibody can respond to endotoxin from many gram-negative bacteria, not just one. A high result is not specific to a single organism and should not be read as proof of a particular infection.
• Assay variation: without standardized clinical cutoffs, values can differ between labs, so compare results run by the same method where possible.

Making Sense of an Unexpected Result

If your level is high and you have digestive symptoms, the next step is to figure out whether it reflects a leaky, inflamed gut. Companion tests worth pairing with it include total IgA (to confirm your baseline antibody production is normal), a broader intestinal barrier antibody panel, a general inflammation marker like hs-CRP (high-sensitivity C-reactive protein), and a stool inflammation marker such as calprotectin. A gastroenterologist can help connect these dots.

If your result is high in the setting of a fever, especially after travel to a region where typhoid is common, that is a situation for prompt clinical evaluation and a blood culture, not watchful waiting. If the value is elevated but you feel well and have no symptoms, the reasonable move is to repeat it in a few months and watch the pattern rather than react to one number. In every case, the antibody is one input into a larger picture, and it should be interpreted alongside your symptoms, history, and other tests.